Meningioma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Meningioma – Drugs In Development, 2024 report and make more profitable business decisions.
A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.
The Meningioma drugs in development market research report provide comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningioma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Meningioma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Meningioma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Meningioma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Meningioma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advanced Accelerator Applications SAAptaBio Therapeutics Inc
Ariceum Therapeutics GmbH
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Changzhou Qianhong Bio-Pharma Co Ltd
Chimerix Inc
Clarity Pharmaceuticals Ltd
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Exelixis Inc
Gan & Lee Pharmaceuticals Co Ltd
GSK plc
Ikena Oncology Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
Nascent Biotech Inc
Neonc Technologies Inc
OncoTherapy Science Inc
Progenics Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Simcere Pharmaceutical Group Ltd
SonALASense Inc
Takeda Pharmaceutical Co Ltd
University of Bradford
Vivace Therapeutics Inc
Wuhan Binhui Biopharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Meningioma reports